5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

2. argenx SE (NASDAQ:ARGX)

Biotechnology Value Fund’s Stake Value: $196million

Percentage of Biotechnology Value Fund’s 13F Portfolio: 7.35% 

Number of Hedge Fund Holders: 27

Mark Lampert’s Biotechnology Value fund increased its existing position in argenx SE (NASDAQ:ARGX) by 110% during the second quarter to make it the second-largest stock holding of its 13F portfolio. Shares of argenx struggled in the past couple of months amid broader market trends. Besides short-term volatility, its stock price soared from its IPO price of $20 in June 2017 to around $281 at present.

At the end of the second quarter, argenx SE was in 27 hedge funds portfolios, flat compared to the previous quarter. Baker Bros. Advisors and VenBio Select Advisor were the leading stakeholders in the company while Biotechnology Value Fund was the fourth largest stakeholder.